Looking for practical insights on managing CIDP? Listen to the Navigating CIDP podcast, hosted by Mark Stettner, to hear expert discussions on key diagnostic considerations and therapeutic strategies. Available on Medthority's Rare Disease Nexus

ow.ly/EZOG50YNX3h

Researchers eye potential Down syndrome fix via advanced gene editing Researchers have developed a modified version of the CRISPR gene-editing tool that in early laboratory experiments suggests it may have the potential to “silence” the extra chromosome that causes Down...

📰 It’s News‑day Tuesday! Early lab research suggests gene‑editing techniques could one day help address the extra chromosome in Down syndrome. Plus, proof‑of‑concept studies show immune cells can be engineered to produce rare protective antibodies

ow.ly/5AzF50YNqAn

Anita D’Souza returns in the latest episode of our #PodcastSeries, Navigating AL Amyloidosis, to discuss individualizing treatment in AL amyloidosis, from covering prognostic biomarkers to response assessment and tailored clinical decision‑making. Available now

ow.ly/r4fR50YMJ8w

To mark #InternationalPompeDay, new survey data highlight persistent challenges in late‑onset Pompe disease care, from delayed diagnostic journeys to unmet supportive needs. Read the latest insights

ow.ly/MWZ550YJQ4i

This #InternationalPompeDay, watch Benedikt Schoser, Priya Sunil Kishnani, and Tahseen Mozaffar discuss unmet needs in late‑onset Pompe disease, now available on the NEW Medthority Rare Disease Nexus for expert insights and CME

ow.ly/48j650YJNVg

Health Rounds: New procedure dramatically improves combat-related PTSD An advanced version of a procedure that uses magnetic fields to stimulate brain nerve cells appears to be extremely effective for combat-related post-traumatic stress disorder, according to a study of...

📰It’s News‑day Tuesday! A novel brain‑stimulation procedure with psychotherapy significantly reduced symptoms in soldiers and veterans with combat‑related PTSD. Plus, research highlights sex‑specific differences in brain changes in Alzheimer’s disease

ow.ly/WZaN50YIMIB

From standards of care to emerging treatment strategies, Ashish Kamat and Joshua Meeks discuss how clinicians approach non‑muscle‑invasive bladder cancer in real‑world practice today🎧

ow.ly/ZMqw50YH36B

#BladderCancer #MedicalEducation #Oncology

What questions do people with myasthenia gravis (MG) rarely ask – but clinicians should? 🎥 John Vissing highlights practical, patient‑centred questions to uncover symptom burden, fatigue, mental health, and treatment expectations in everyday MG care

ow.ly/Wp2y50YGCGr

Surgery to cure early-stage lung cancer appears safe even over age 80 (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy LapidApril 3 (Reuters) - Doctors should no

📰It's News‑day Tuesday! Surgery for early‑stage lung cancer may be safe and effective in patients over 80. Plus, poison control data reveal a sharp rise in kratom‑related overdoses in the U.S
#MedSky #MedicalNews #MedEd

ow.ly/hHkq50YF2RG

🌍 World Health Day
Access trusted, independent medical education this #WorldHealthDay. Medthority supports healthcare professionals with free, on‑demand resources, developed with leading experts to inform practice and improve patient care

ow.ly/86MJ50YEVpC

Health Rounds: Researchers find biomarker that could lead to improved schizophrenia treatments Researchers have identified a biomarker linked to schizophrenia that could lead to new treatments to tackle symptoms of the debilitating mental disorder not addressed by current medicines.

📰 It’s News‑day Tuesday! A newly-identified brain biomarker linked to schizophrenia could support more targeted treatments. Plus, researchers report early success using a virus to combat antibiotic‑resistant Salmonella

ow.ly/76PO50YBgki

#MedEd #MedSky #medicaleducation

Ending #EndometriosisAwarenessMonth by spotlighting new research that could help identify cases missed by imaging.

Read more below 👇

#Endometriosis #MedEd

What do you think about Medthority? Tell us about your experience so far and what you’d like to see next. Your feedback helps us build better #medicaleducation for busy healthcare professionals like you

ow.ly/poZ350YzchT

Listen to our NEW Navigating CIDP podcast series, now available on demand with Medthority. Join Mark Stettner, Luis Querol, and Filip Eftimov as they discuss the evolving challenges of diagnosing and managing #CIDP in real-world practice

ow.ly/yOEi50YyLme

📰 It’s News‑day Tuesday! A new blood test may improve detection of endometriosis, identifying cases missed by imaging. Plus, early trial data suggest a novel oral approach could improve function in people living with ALS

ow.ly/LE5050Yy2o6

#MedSky #MedicalNews #MedEd

Navigate secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) with insights from experts in our on-demand podcast series. Hear Michael Jordan, and expert guests discuss evolving treatments and diagnostic challenges 🎧

ow.ly/Tr5b50YxYLF

Heading to #THSNA2026? Which VTE trial do you think had the biggest impact in 2025 and why? Hear expert perspectives from Geoffrey Barnes, Marc Carrier, Edelgard Lindhoff-Last, and Marco Proietti in this roundtable discussion, free and on-demand

ow.ly/iQeu50YvVvl

Health Rounds: Death from dementia on the rise among people with type 2 diabetes In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.

📰 It’s News‑day Tuesday! Dementia‑related deaths are rising among people with type 2 diabetes, despite declines in cardiovascular mortality. Plus, low testosterone may signal which patients with prostate cancer need closer active surveillance

ow.ly/oAUq50YviFA

Gain insights on early multi-system clues in #AATD and how emerging RNA and gene-based therapies could shape future care. Jorge Lascano and Gerry McElvaney share guidance on coordinated lung–liver management and evolving treatment pathways

ow.ly/T0NF50YvgSW

Listen to the latest episode of Unlocking Myasthenia Gravis to hear Nils Erik Gilhus and Gil Wolfe discuss thymectomy in #MyastheniaGravis, covering patient selection, age considerations, and evolving treatment strategies

Available now on Medthority
ow.ly/RVHv50YsrEC

📰 It’s News‑day Tuesday! New research links a Parkinson’s‑related protein to faster Alzheimer’s progression in women. Plus, an experimental therapy shows promising seizure reduction in children with a rare genetic epilepsy

ow.ly/pgIS50YrLf4

#MedEd #MedSky

Catch up with the latest episodes of our #PodcastSeries as Shaji Kumar is joined by Taxiarchis Kourelis and Vaishali Sanchorawala to discuss practical steps in recognizing #ALAmyloidosis early, plus emerging modalities that may impact standard care

ow.ly/Yt1I50Yrrkr

Read the latest insights from #GU26

From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches

ow.ly/tuHe50Ypb0U

#ASCOGU #ASCOGU2026 #MedEd #MedSky

It’s News‑day Tuesday! Does intensifying treatment improve outcomes? At #GU26, Karim Fizazi unpacks first PEACE‑2 results—finding no clinical benefit beyond long‑term ADT + radiotherapy in very high‑risk localized prostate cancer

ow.ly/sQ9G50Yoxrz

What’s holding back routine HRR testing in #ProstateCancer care?

Watch Arun Azad unpack common misconceptions, real‑world workflow challenges, and why education is critical to ensuring patients don’t miss access to PARP inhibitors.

ow.ly/lbgr50Yoatp

#MedEd #Oncology #MedSky

That’s a wrap for this oral abstract session on IMvigor011 trial at #GU26

Missed any insights? Explore on demand congress coverage and expert perspectives on Medthority

ow.ly/zJpy50Yn3UP

Dr. Bellmunt concludes IMvigor011:

🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk

💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS

#GU26 #BladderCancer #MIBC

🔬 Dr. Bellmunt presents IMvigor011: early ctDNA positivity after RC was frequent and typically detected within <24 wks

📉Baseline ctDNA levels differed by risk group, and ctDNA kinetics showed clear divergence between arms over time

#GU26 #BladderCancer #MIBC #Oncology

Can ctDNA timing and dynamics refine adjuvant treatment decisions in #MIBC?
Follow our #GU26 coverage for new insights from Joaquim Bellmunt on the IMvigor011 trial

#BladderCancer #Oncology #MedSky #MedEd

That concludes our live coverage on the KEYNOTE-B15 trial. Stay tuned for the oral abstract session on the IMvigor011trial starting at 16:57 BST/08:57 PST 🕔